^
Association details:
| Biomarker: | BRAF T1799A |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + Ceraxa (nanoliposomal ceramide) (Apoptosis inducer, PP2A activator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development
Excerpt:
...MDA-MB-231 breast cancer cells treated with 0.25 μmol/L sorafenib or 1.5 μmol/L nanoliposomal ceramide showed a 10% to 13% reduction in cell viability with single agents compared with an ∼46% decrease with combined agents, which was an approximately 4- to 5-fold increase in efficacy compared with single agents.
DOI:
10.1158/1078-0432.CCR-07-4881
